Loading
Life sciences · Journal article
Journal of the American Chemical Society · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Extracellular vesicles (EVs) are critical mediators of tumor-stromal communication within the tumor microenvironment (TME), where reciprocal signaling between cancer cells and cancer-associated fibroblasts (CAFs) fuels malignant progression and therapeutic resistance. Here, we report a degrader-antibody conjugate (DAC) platform, Ctx-ETAC, in which the clinically approved anti-EGFR antibody cetuximab (Ctx) delivers an engineered proteolysis-targeting chimera (PROTAC) payload, ETAC, selectively into EGFR-expressing tumor cells and activated CAFs via receptor-mediated endocytosis. ETAC integrates indomethacin as the COX-2 ligand, a VHL-recruiting peptide, and a cathepsin B (Cat-B)-cleavable azidoacetyl-RR linker; conjugation to Ctx was achieved by a two-step bioorthogonal strategy, yielding an average drug-to-antibody ratio of 4.21. The resulting Ctx-ETAC ensures biomarker-selective payload activation in both tumor cells and activated CAFs, markedly reducing EV secretion by 95.5% and thereby disrupting their crosstalk. This disruption of EV-mediated communication reprograms CAFs toward a quiescent phenotype and reshapes the non-small cell lung cancer microenvironment into an antitumor state. In a xenograft model, Ctx-ETAC achieves markedly superior tumor suppression compared with Ctx monotherapy, without systemic toxicity. These findings establish receptor-guided targeted protein degradation as a strategy to disrupt EV-driven tumor-stromal communication and provide a new framework for microenvironment-directed cancer therapy.